Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN12 | Q05209 | 1/20 | 0.52 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 7/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.51 |
| ▸ | MMP3 | P08254 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24559308 | 0.93 | ADORA2B (0.53) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL24559333 | 0.92 | MAPT (0.55) | AKR1B1PTPN1KMT2AMEN1MAPT | |
| SCHEMBL24559334 | 0.85 | MAPT (0.55) | AKR1B1PTPN1KMT2AMEN1MAPT | |
| SCHEMBL24559279 | 0.78 | MYC (0.52) | — | |
| SCHEMBL24666143 | 0.77 | LMNA (0.58) | POLBMAPTALDH1A1 | |
| SCHEMBL24559153 | 0.77 | LMNA (0.51) | KMT2AMEN1POLBMAPTKDM4E | |
| SCHEMBL10417661 | 0.75 | PTPN12 (0.73) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL10417660 | 0.75 | PTPN12 (0.73) | PTPN12PTPN22AKR1B1PTPN1MMP3 | |
| SCHEMBL22521806 | 0.73 | SMN1; SMN2 (0.76) | POLBMAPTALDH1A1 | |
| SCHEMBL15330386 | 0.73 | PTPN12 (0.79) | PTPN12PTPN22AKR1B1PTPN1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202821-A1 | SMALL MOLECULE PARG INHIBITORS AND METHODS OF USE THEREOF | PARG, PARP15, PLG | PTPN12 3642/4885PTPN22 3146/4885AKR1B1 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.